| # | Title | Journal | Year | Citations |
|---|
| 1 | Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Nature | 1995 | 4,277 |
| 2 | Identification of a major co-receptor for primary isolates of HIV-1 | Nature | 1996 | 3,667 |
| 3 | HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time | Science | 1996 | 3,161 |
| 4 | Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection | Cell | 1996 | 2,964 |
| 5 | Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Journal of Virology | 1994 | 2,307 |
| 6 | Extrapulmonary manifestations of COVID-19 | Nature Medicine | 2020 | 2,300 |
| 7 | A diverse range of gene products are effectors of the type I interferon antiviral response | Nature | 2011 | 2,054 |
| 8 | Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 | Nature | 2021 | 1,904 |
| 9 | The role of a mutant CCR5 allele in HIV–1 transmission and disease progression | Nature Medicine | 1996 | 1,346 |
| 10 | Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals | Journal of Experimental Medicine | 1997 | 1,346 |
| 11 | Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike | Nature | 2020 | 1,337 |
| 12 | Genotypic and phenotypic characterization of HIV-1 patients with primary infection | Science | 1993 | 1,336 |
| 13 | Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes | Virology | 1995 | 1,262 |
| 14 | Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry | Nature | 2007 | 1,082 |
| 15 | Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Science | 1994 | 1,080 |
| 16 | Identification of microRNAs of the herpesvirus family | Nature Methods | 2005 | 1,073 |
| 17 | Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection | New England Journal of Medicine | 1995 | 1,065 |
| 18 | Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Journal of Virology | 1996 | 1,039 |
| 19 | Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 | Nature | 2022 | 1,038 |
| 20 | Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract | Journal of Experimental Medicine | 2004 | 986 |
| 21 | Recognition of bacterial glycosphingolipids by natural killer T cells | Nature | 2005 | 865 |
| 22 | Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity | Journal of Virology | 1995 | 857 |
| 23 | HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function | Journal of Experimental Medicine | 2000 | 820 |
| 24 | Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Nature | 2009 | 806 |
| 25 | Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy | New England Journal of Medicine | 1999 | 782 |
| 26 | Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. | Journal of Experimental Medicine | 1996 | 690 |
| 27 | Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures | Nature Medicine | 1996 | 676 |
| 28 | Antibody evasion properties of SARS-CoV-2 Omicron sublineages | Nature | 2022 | 649 |
| 29 | Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria | Nature Immunology | 2006 | 567 |
| 30 | Endogenous Viral Elements in Animal Genomes | PLoS Genetics | 2010 | 565 |
| 31 | A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids | Cell Stem Cell | 2020 | 543 |
| 32 | Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 | Nature | 2022 | 541 |
| 33 | Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells | Cell | 2009 | 517 |
| 34 | Progesterone implants enhance SIV vaginal transmission and early virus load | Nature Medicine | 1996 | 513 |
| 35 | Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Lancet, The | 2007 | 506 |
| 36 | Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization | Cell Host and Microbe | 2021 | 504 |
| 37 | A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure | Journal of Virology | 2000 | 503 |
| 38 | Contribution of Human -Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor | Science | 2002 | 499 |
| 39 | HIV/AIDS epidemiology, pathogenesis, prevention, and treatment | Lancet, The | 2006 | 496 |
| 40 | Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals | Journal of Virology | 1993 | 487 |
| 41 | Towards an HIV cure: a global scientific strategy | Nature Reviews Immunology | 2012 | 485 |
| 42 | Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG | Journal of Virology | 1995 | 483 |
| 43 | A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection | New England Journal of Medicine | 1995 | 482 |
| 44 | An African HIV-1 sequence from 1959 and implications for the origin of the epidemic | Nature | 1998 | 479 |
| 45 | HIV therapy by a combination of broadly neutralizing antibodies in humanized mice | Nature | 2012 | 463 |
| 46 | Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis | Lancet, The | 1999 | 458 |
| 47 | Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants | Cell | 2023 | 455 |
| 48 | MX2 is an interferon-induced inhibitor of HIV-1 infection | Nature | 2013 | 445 |
| 49 | Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite | Cell Host and Microbe | 2021 | 444 |
| 50 | The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy | Nature Medicine | 2000 | 435 |
